04/05/2022 - Press release
The Biomedical Informatics Research Programme of IMIM-Hospital del Mar has received one of the European Research Council (ERC) grants for the NovoGenePop project, the ERC Advanced Grant. Among the 253 researchers selected, only thirteen are from Spain. The project at the IMIM-Hospital del Mar, the only Spanish biomedical research centre to be selected, will develop bioinformatics tools to identify specific genes in certain individuals or populations. This may pave the way for accelerated research in fields such as cancer and hereditary diseases. In total, the ERC Advanced Grants have distributed 624 million between 253 European researchers. This is the fourth grant of this type that the IMIM-Hospital del Mar has received in the last years.
28/04/2022 - Press release
The study was carried out jointly by Germans Trias Hospital and the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar). The research team compared blood samples from 58 cases of patients hospitalised for heart attack complicated by primary ventricular fibrillation with those of 116 people who did not suffer this complication. A team of researchers from Germans Trias Hospital, the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the CIBER on cardiovascular diseases has demonstrated that regular consumption of foods rich in linoleic acid can help to reduce the risk of cardiac arrest due to ventricular fibrillation during the acute phase of a heart attack. The results of the study have been published in the journal Scientific Reports.
21/04/2022 - General information
The research project PROMES-U has been launched with the goal of enhancing the mental health of university students through the exploration of factors influencing the onset of mental health issues. Additionally, the project aims to implement and evaluate online interventions for promoting mental well-being and preventing problems related to depression and anxiety. The study is led by the Hospital del Mar Medical Research Institute (IMIM) and involves participation from UPF, the University of the Balearic Islands, Jaume I University of Castellón, Miguel Hernández University of Elche, and the University of Zaragoza.
Més informació "PROMES-U Study Initiated to Promote Student Mental Health"
19/04/2022 - General information
The VALAWAI project, led by the CSIC with the participation of the Hospital del Mar Medical Research Institute and the Hospital del Mar, has received nearly four million euros from the European Innovation Council under the Pathfinder Challenges. A team from the Neuroimaging of Mental Disorders Research Group at the Hospital del Mar Medical Research Institute, led by Dr. Òscar Vilarroya, along with the Innovation Directorate of the Hospital del Mar, headed by Dr. Jordi Martínez, is part of the VALAWAI project (Value-Aware Artificial Intelligence). The project has recently been granted European funding of nearly four million euros. Its objective is to develop a set of tools for creating artificial intelligence systems that incorporate mechanisms sensitive to human values. In other words, these systems should be capable of deciding whether certain actions are morally acceptable and be aware of their users' value systems.
12/04/2022 - Press release
COVID-19 has accelerated the need to raise awareness of the psychological well-being of the human teams that form part of SME organisations, in the face of the economic uncertainty aggravated by the war in Ukraine.
31/03/2022 - General information
The project "Tumour microenvironment-derived factors in localised colon cancer: clinical impact and therapeutic implications' (TuMiCC)"aimed at demonstrating the value of the tumour microenvironment in predicting relapse in patients with localised colon cancer treated with adjuvant therapy, has reached the 16-month development milestone, with patient recruitment and interesting advances in the molecular characterisation of this type of tumour and its environment.
30/03/2022 - General information
A study by the Neuroimmunology Research Group at the Hospital del Mar Medical Research Institute (IMIM) has validated a possible marker that could improve the efficiency of one of the main multiple sclerosis treatments. The marker is a specific type of immune system cell, known as NK (Natural Killer) cells, which express a specific receptor on their surface, NKG2C. Currently, patients with multiple sclerosis are treated with anti-CD20 monoclonal antibodies, which are designed to eliminate the B-lymphocyte population in peripheral blood and thus control disease activity. These drugs are scheduled to be administered once every six months, although it is unclear whether this time period is appropriate for all patients. Several studies indicate that, depending on the drug given, it takes between six months and a year and a half for the levels of the B-lymphocyte population to recover.
23/03/2022 - Events
From 25 April to 20 June, 2022, the series "Our brain, that great unknown" will be held in various libraries across Barcelona, supported by the Barcelona library network. This series is part of the "Visions of Science" project organised by the Barcelona Library network, and for the third year it has been entrusted to the Hospital del Mar Medical Research Institute (IMIM) thanks to the success of previous editions. The series will run for 8 weeks. Every Monday at 6:30 pm there will be free talks, open to everyone, on topics related to the brain, a complex and fascinating organ about which we still have a great deal to discover. In this series we will learn about the latest data provided by new scientific advances in this field thanks to the participation of leading experts from Hospital del Mar and the IMIM. We will find out everything from how the brain works and how it behaves in the face of illness to how emotions are seen in the brain and the latest brain surgery techniques.
23/03/2022 - General information
The European Research Network on Signal Transduction (ERNEST), of which IMIM is a member, has created an Emergency Fund for Ukrainian researchers. Researchers affiliated to any legal entity in Ukraine (for example, schools and universities, research centers, governmental institutions, or private companies) are eligible to apply for this funding. For more information you can contact Jana Selent (vice-chair of the ERNEST - Cost Action 18133) or visit this website
17/03/2022 - Press release
Researchers at the Hospital del Mar Medical Research Institute and Hospital del Mar have transformed immunotherapy-resistant tumours into tumours that respond to this treatment, achieving cures in animal models through an innovative therapeutic strategy in triple-negative breast cancer, the most aggressive subtype. Researchers have discovered the essential role of a new factor, LCOR, in enabling cancer cells to present tumour antigens on their surfaces. These antigens allow the immune system to recognise the tumour, an essential step if immunotherapy treatment is to succeed. On the other hand, they have shown that cancer stem cells have very low levels of LCOR, making them invisible to the immune system and therefore resistant to treatment. The work that has just been published used an innovative experimental messenger RNA system, similar to the technology used for COVID-19 vaccines, to produce LCOR in tumour cells. In this way, the resistant tumour cells of triple-negative cancer become visible and sensitive to the immune system. This approach is also being investigated in other breast cancer subtypes
Més informació "Radical increase in the effectiveness of breast cancer immunotherapy"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
